-
10m 8s
Explore the latest European Society of Cardiology (ESC) guidelines on renal denervation (RDN) and what they mean for clinicians.
This video series delves into the new recommendations and explains how they fit into the broader context of existing guidelines. Prof Andrew Sharp and Dr Joost Daemen discuss how these updates might influence daily practice, addressing whether we’ll see more frequent use of RDN in the future. The necessary steps are explored to ensure that RDN becomes a standard part of routine care. Ideal for busy clinicians, this content provides actionable insights into integrating these guidelines into practice.
More from this programme
Part 1
ESC Guidelines 2024 – What’s New?
| 1 session | |
| ESC Guidelines 2024 – What’s New? | Watch now |
Part 2
Putting ESC Guidelines Into Clinical Practice
Faculty Biographies
Andrew SP Sharp
Professor of Cardiology
Andrew Sharp qualified from Edinburgh Medical School in 1998 and subsequently pursued an MD postgraduate research degree at the University of Edinburgh. His doctoral research focused on the hypertensive heart, establishing a foundation for his ongoing clinical and academic interest in hypertension and cardiovascular disease.
Clinical Training & Early Career
Dr Sharp completed his early clinical training at the Royal Infirmary of Edinburgh before moving to London for senior clinical training at the hospitals of Imperial College London. He then undertook the prestigious Milan-Imperial Interventional Cardiology Fellowship programme, which included a year in Milan at San Raffaele and Columbus Hospitals, where he trained under leading experts in interventional cardiology. This combination of UK and international training shaped his expertise in complex coronary interventions and device-based therapies.
Career Progression
- In…
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.